Back

Progression of markers of cardiac structure and function in the Personalised prospective comparison of ARni with ArB in patients with natriuretic peptide eLEvation (PARABLE) clinical trial

25 May 2019 (00:00 - 00:00)
Organised by:
Congress Presentation Part of: Poster Session 1 - Pharmacology and Pharmacotherapy Cardiovascular Pharmacotherapy, Other HFA Premium Access Heart Failure 2019

About the speaker

Photo
Professor Mark Ledwidge

STOP-HF Unit, Dublin (Ireland)

10 More presentations in this session

Presentation thumbnail
Sacubitril valsartan in real life: tolerance, clinical evolution and remodeled long term
Doctor R. Bravo-Marques (Marbella, ES)
Abstract
Presentation thumbnail
Security of neurohormonal blocking with sacubitril / valsartan, iSGLT2 and mineralocorticoid receptor antagonist in patients with heart failure with reduced eyection fraction and diabetes mellitus
Doctor R. Bravo-Marques (Marbella, ES)
Abstract
Presentation thumbnail
Improvement of NT-proBNP and NYHA values in patients with HFrEF and Sacubitril/Valsartan treatment
Doctor C. Goena Vives (Donostia, ES)
Abstract Slides
Presentation thumbnail
Long-term prognostic impact of beta-blocker prescription during hospitalization for acute myocardial infarction
Doctor F. Fonseca Goncalves (Vila Real, PT)
Abstract Slides
Presentation thumbnail
Diabetic patients need higher loop diuretic doses: a report on acute and chronic heart failure patients
Associate Professor P. Bettencourt (Porto, PT)

Access the full session

Session thumbnail
Poster Session 1 - Pharmacology and Pharmacotherapy

The Event

Event poster

Heart Failure 2019

25 May - 28 May 2019

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources